Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 1,014 Shares of Stock

Key Points

• CFO Christopher Cline sold 1,014 shares on April 15 at an average price of $42.61 under a Rule 10b5‑1 plan to cover tax withholding, trimming his stake by 0.86% to 116,899 shares.
• FDA full approval for Filspari in FSGS materially expands Travere’s U.S. addressable market (~30,000 patients) and sparked a ~37% stock surge and several analyst price‑target upgrades.
• Shares traded down 2.8% to $40.95 on heavy volume amid heightened options activity; the company has a $3.78B market cap and a consensus rating of "Moderate Buy" with an average target of $42.50.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 1,014 shares of Travere Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $42.61, for a total transaction of $43,206.54. Following the sale, the chief financial officer owned 116,899 shares of the company's stock, valued at approximately $4,981,066.39. This trade represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Trading Down 2.8%

Shares of NASDAQ:TVTX traded down $1.18 during midday trading on Wednesday, reaching $40.95. The company's stock had a trading volume of 4,521,912 shares, compared to its average volume of 2,203,580. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -136.50 and a beta of 0.86. The business has a 50 day moving average price of $29.57 and a 200 day moving average price of $31.37. Travere Therapeutics, Inc. has a 1 year low of $13.88 and a 1 year high of $43.31. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71.

Analyst Ratings Changes

A number of research firms recently issued reports on TVTX. Piper Sandler upgraded shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 target price for the company in a report on Tuesday. Wedbush increased their price target on shares of Travere Therapeutics from $39.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday. JPMorgan Chase & Co. decreased their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, March 25th. Wall Street Zen cut shares of Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Finally, HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System increased its stake in Travere Therapeutics by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 24,964 shares of the company's stock worth $597,000 after buying an additional 375 shares during the period. Smartleaf Asset Management LLC boosted its position in Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock valued at $45,000 after buying an additional 487 shares during the last quarter. Comerica Bank grew its stake in shares of Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after acquiring an additional 492 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Travere Therapeutics by 4.1% during the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company's stock worth $726,000 after acquiring an additional 756 shares during the last quarter. Finally, Diversified Trust Co lifted its stake in shares of Travere Therapeutics by 3.5% in the third quarter. Diversified Trust Co now owns 23,695 shares of the company's stock worth $566,000 after acquiring an additional 796 shares in the last quarter.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.